The Incidence of Abdominal and Pelvic Surgery Among Patients with Irritable Bowel Syndrome

被引:0
作者
J. Alexander Cole
Jason M. Yeaw
Jennifer A. Cutone
Braden Kuo
Zhiping Huang
David L. Earnest
Alexander M. Walker
机构
[1] Ingenix,Department of Epidemiology
[2] Riverside Center 3-120,undefined
来源
Digestive Diseases and Sciences | 2005年 / 50卷
关键词
irritable bowel syndrome; abdominal surgery; pelvic surgery; gallbladder surgery; managed care; epidemiology;
D O I
暂无
中图分类号
学科分类号
摘要
Rates of abdominopelvic surgery, with a particular focus on gallbladder procedures, were measured in patients with irritable bowel syndrome (IBS) (n= 108,936) and compared with those in a general population sample (n= 223,082). The patient sample was selected from persons who were members of a managed care organization during the years 1995–2000. Medical records from a randomly selected subset of IBS patients were reviewed to confirm the diagnosis. Crude and standardized rates and adjusted rate ratios for surgery were calculated. The incidence of abdominopelvic surgery, excluding gallbladder procedures, was 87% higher in patients with IBS than that for the general population. The incidence of gallbladder surgery was threefold higher in IBS patients than the general population. Patients with IBS have an increased risk for abdominopelvic and gallbladder surgery and, thus, an associated risk for experiencing morbidity and mortality associated with these surgical procedures.
引用
收藏
页码:2268 / 2275
页数:7
相关论文
共 40 条
[1]  
Talley NJ(1995)Irritable bowel syndrome in a community: symptom subgroups, risk factors, and health care utilization Am J Epidemiol 142 76-83
[2]  
Zinsmeister AR(2001)The irritable bowel syndrome N Engl J Med 344 1846-1850
[3]  
Melton LJ(2000)Epidemiology of cholecystectomy and irritable bowel syndrome in a UK population Br J Surg 87 1658-1663
[4]  
Horwitz BJ(2003)Systematic review: Abdominal and pelvic surgery in patients with irritable bowel syndrome Aliment Pharmacol Ther 17 997-1005
[5]  
Fisher RS(2002)Safety and tolerability of tegaserod in patients with irritable bowel syndrome and diarrhea symptoms Am J Gastroenterol 97 1176-1181
[6]  
Kennedy TM(2003)An Asia-Pacific, double blind, placebo controlled, randomised study to evaluate the efficacy, safety, and tolerability of tegaserod in patients with irritable bowel syndrome Gut 52 671-676
[7]  
Jones RH(2001)Tegaserod, a 5-HT(4) receptor partial agonist, relieves symptoms in irritable bowel syndrome patients with abdominal pain, bloating and constipation Aliment Pharmacol Ther 15 1655-1666
[8]  
Hasler WL(2002)A randomized, double-blind, placebo-controlled trial of tegaserod in female patients suffering from irritable bowel syndrome with constipation Aliment Pharmacol Ther 16 1877-1888
[9]  
Schoenfeld P(1995)Use of insurance claims in epidemiologic research: Identification of peptic ulcers, GI bleeding, pancreatitis, hepatitis and renal disease Pharmacoepidemiol Drug Saf 4 239-248
[10]  
Fidelholtz J(1993)Using claims data for epidemiologic research. The concordance of claims-based criteria with the medical record and patient survey for identifying a hypertensive population Med Care 31 498-507